PharmaBlock Sciences Nanjing Inc
SZSE:300725
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
PharmaBlock Sciences Nanjing Inc
Accounts Receivables
PharmaBlock Sciences Nanjing Inc
Accounts Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
PharmaBlock Sciences Nanjing Inc
SZSE:300725
|
Accounts Receivables
¥345.3m
|
CAGR 3-Years
2%
|
CAGR 5-Years
31%
|
CAGR 10-Years
N/A
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Accounts Receivables
¥3.1B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Accounts Receivables
¥5.1B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
9%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Accounts Receivables
¥10.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
23%
|
CAGR 10-Years
25%
|
|
|
Zhejiang Nhu Co Ltd
SZSE:002001
|
Accounts Receivables
¥3.3B
|
CAGR 3-Years
10%
|
CAGR 5-Years
12%
|
CAGR 10-Years
16%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Accounts Receivables
¥106.7m
|
CAGR 3-Years
0%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
N/A
|
|
PharmaBlock Sciences Nanjing Inc
Glance View
PharmaBlock Sciences (Nanjing), Inc. engages in the innovation of chemistry products and services throughout the pharmaceutical research and development process. The company is headquartered in Nanjing, Jiangsu and currently employs 1,735 full-time employees. The company went IPO on 2017-11-10. The firm's primary products include aromatic heterocyclic drug molecular building blocks, common saturated alicyclic drug molecular building blocks, four-membered ring drug molecular building blocks and special saturated ring drug molecular building blocks. The firm is also involved in development, production and sales of pharmaceutical intermediates, and provides technical services related to the development and process production of pharmaceutical molecular building blocks.
See Also
What is PharmaBlock Sciences Nanjing Inc's Accounts Receivables?
Accounts Receivables
345.3m
CNY
Based on the financial report for Sep 30, 2025, PharmaBlock Sciences Nanjing Inc's Accounts Receivables amounts to 345.3m CNY.
What is PharmaBlock Sciences Nanjing Inc's Accounts Receivables growth rate?
Accounts Receivables CAGR 5Y
31%
Over the last year, the Accounts Receivables growth was -13%. The average annual Accounts Receivables growth rates for PharmaBlock Sciences Nanjing Inc have been 2% over the past three years , 31% over the past five years .
